Xtandi 40 mg Capsule

Description

Xtandi 40 mg Tablet contains enzalutamide, an oral anticancer medicine classified as an androgen receptor inhibitor. It is used in the treatment of prostate cancer, particularly in cases where the disease has spread beyond the prostate or continues to progress despite reduced testosterone levels. Prostate cancer cells often depend on male hormones called androgens (such as testosterone) to grow. Enzalutamide works by blocking the activity of these hormones in cancer cells. Xtandi interferes with the androgen receptor signaling pathway by preventing androgens from binding to their receptors and by inhibiting the movement of these receptors into the cell nucleus where they activate genes responsible for tumor growth. By disrupting this process, the medicine may help slow the progression of prostate cancer when taken as prescribed by a qualified healthcare professional. Xtandi tablets are t

Benefits

• Blocks androgen receptor signaling, a key driver of prostate cancer growth

• Oral targeted therapy suitable for outpatient treatment

• Used in various stages of advanced prostate cancer

• Can be used alongside androgen deprivation therapy

• Part of modern hormone therapy approaches for prostate cancer

Indications and Usage

Xtandi (enzalutamide) may be prescribed for:

• Metastatic castration-resistant prostate cancer (mCRPC)

• Non-metastatic castration-resistant prostate cancer (nmCRPC)

• Metastatic hormone-sensitive prostate cancer (mHSPC)

• Patients undergoing androgen deprivation therapy (ADT) for prostate cancer

Treatment decisions are based on disease stage, prior therapies, and clinical evaluation.

How it Works

Enzalutamide works by inhibiting the androgen receptor signaling pathway, which plays a central role in the development and progression of prostate cancer. Androgens such as testosterone normally bind to androgen receptors in prostate cells and activate genes that promote cell growth.

Xtandi blocks this process in several ways. It prevents androgens from binding to the receptor, inhibits the receptor’s movement into the cell nucleus, and interferes with its ability to activate growth-related genes. By disrupting these signals, enzalutamide helps reduce cancer cell growth and slow disease progression when used as prescribed and monitored by a healthcare professional.

Dosage & Administration

• Xtandi tablets are taken orally once daily, unless directed otherwise by a healthcare professional.

• Tablets should be swallowed whole with water.

• The medicine may be taken with or without food.

• Dose adjustments may be necessary depending on tolerance or side effects.

• Treatment duration is determined by the treating physician based on clinical response.

Side Effects

Common side effects

• Fatigue

• Hot flashes

• Joint pain

• Decreased appetite

• High blood pressure

• Diarrhea

Serious side effects

• Seizures (rare)

• Falls and fractures

• Heart-related complications

• Severe allergic reactions

• Neurological symptoms

Patients should seek medical attention if severe symptoms occur.

Warning and Precaution

• Risk of seizures, particularly in patients with neurological conditions

• Possible high blood pressure and cardiovascular effects

• Increased risk of falls and fractures

• Monitor liver function and overall health during treatment

• Inform healthcare providers about all medications and supplements being used

• Pregnancy exposure should be avoided due to potential fetal harm

Patient Guidance

• Take the medicine exactly as prescribed by your healthcare provider

• Attend scheduled medical monitoring and follow-up visits

• Report symptoms such as seizures, severe fatigue, or dizziness

• Inform your doctor about all medications or supplements being used

• Follow guidance regarding bone health and cardiovascular monitoring

• Do not stop treatment without consulting your healthcare provider

Clinical Trial & Approvals

Enzalutamide has been studied in several major clinical trials, including the AFFIRM, PREVAIL, and PROSPER studies, which demonstrated improved outcomes in patients with advanced prostate cancer. Based on these results, enzalutamide has received regulatory approvals from agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for multiple prostate cancer indications.

References

• U.S. Food and Drug Administration (FDA) – Enzalutamide Prescribing Information
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203415s024lbl.pdf

• European Medicines Agency (EMA) – Xtandi (enzalutamide) Product Information
  https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi

• National Cancer Institute – Enzalutamide Drug Information
  https://www.cancer.gov

• Drugs.com – Enzalutamide Drug Information
  https://www.drugs.com

• ClinicalTrials.gov – Enzalutamide Clinical Studies
  https://clinicaltrials.gov

Prescription & documentation note

Xtandi 40 mg Tablet is typically supplied against a valid prescription. For international orders, patients may need to provide documentation such as a licensed physician’s prescription, identification, and country-specific import documentation, depending on destination regulations. MedsMonk may assist with documentation guidance where applicable.